Daiichi Sankyo

News

AZ/Daiichi's Enhertu gains second 'breakthrough' tag in spac...

The FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the space of a week that the drug has received the

Views & Analysis

Daiichi Sankyo: pharma needs to become NHS ‘experts’

If pharma wants to help the NHS improve outcomes, it needs to do so through a true partnership rather than a transactional relationship.

News

Cost-concerns-with-the-new-NHS-pricing-scheme-2

Current pharma model “not sustainable” during COVID-19, says...

At eyeforpharma Daiichi Sankyo’s Manuel Reiberg spoke about why the industry should look to make drugs more affordable in the wake of the COVID-19 pandemic and “leave the next generation a healt

Views & Analysis

Antibody-drug conjugates on the march

One of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal with Japan’s Daiichi Sankyo, focused on just one breast cancer drug.

News

FDA hastily approves Daiichi Sankyo/AZ's cancer drug, weeks ...

The FDA has approved an advanced breast cancer drug from AstraZeneca and Daiichi Sankyo in super-quick time.

News

AZ and Daiichi Sankyo's breast cancer drug delays progressio...

AstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Sankyo for an experimental breast cancer drug – and so far it looks like money w

AZ/Daiichi's Enhertu gains second 'breakthrough' tag in spac...

Daiichi Sankyo: pharma needs to become NHS ‘experts’

Current pharma model “not sustainable” during COVID-19, says...

Antibody-drug conjugates on the march

FDA hastily approves Daiichi Sankyo/AZ's cancer drug, weeks ...

AZ and Daiichi Sankyo's breast cancer drug delays progressio...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Daiichi Sankyo

Editor's Picks